NEW YORK, March 7, 2017 /Weed Wire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has enrolled 40 patients and commenced its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum.
Tag Archives: IBS
Could cannabis-infused chewing gum be a potential solution for IBS sufferers? The Doctors discuss a new medical trial in the Netherlands with promising results.
NEW YORK, Jan. 18, 2017 /Weed Wire/ — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, has entered clinical trials on treating irritable bowel syndrome (IBS) with the Company’s CanChew Plus® cannabidiol (CBD) gum at Wageningen University in the Netherlands.
On Monday, May 2, 2016, the Illinois Medical Cannabis Advisory Board will meet to discuss the possibility of approving additional conditions for the state’s list of conditions that can qualify a patient to use medical cannabis.
GLENDALE, Colo. — The crowd of approximately 100 veterans, marijuana patients, doctors and activists erupted in cheers at about noon on December 17, 2014.